Maravai LifeSciences (MRVI) to Release Earnings on Thursday

Maravai LifeSciences (NASDAQ:MRVI) will release its earnings data after the market closes on Thursday, November 7th. Analysts expect Maravai LifeSciences to post earnings of $0.00 per share for the quarter. Maravai LifeSciences has set its FY 2024 guidance at EPS.Persons interested in participating in the company’s earnings conference call can do so using this link.

Maravai LifeSciences (NASDAQ:MRVI) last announced its earnings results on Wednesday, August 7th. The company reported ($0.08) earnings per share for the quarter. Maravai LifeSciences had a negative return on equity of 4.78% and a negative net margin of 47.41%. The business had revenue of $73.40 million for the quarter, compared to analysts’ expectations of $71.64 million. During the same quarter last year, the firm earned ($0.06) earnings per share. The firm’s quarterly revenue was up 6.5% compared to the same quarter last year. On average, analysts expect Maravai LifeSciences to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Maravai LifeSciences Stock Up 7.3 %

Shares of MRVI stock opened at $7.63 on Thursday. Maravai LifeSciences has a 1-year low of $4.52 and a 1-year high of $11.56. The stock’s fifty day moving average price is $8.33 and its 200 day moving average price is $8.52. The company has a debt-to-equity ratio of 0.71, a current ratio of 10.00 and a quick ratio of 9.28. The company has a market cap of $1.92 billion and a price-to-earnings ratio of -7.71.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. Wells Fargo & Company assumed coverage on Maravai LifeSciences in a research note on Tuesday, August 27th. They set an “overweight” rating and a $10.00 target price on the stock. Royal Bank of Canada restated an “outperform” rating and set a $15.00 target price on shares of Maravai LifeSciences in a research note on Friday, August 16th. The Goldman Sachs Group dropped their target price on Maravai LifeSciences from $8.00 to $7.00 and set a “neutral” rating on the stock in a research note on Tuesday, October 8th. UBS Group lifted their price target on Maravai LifeSciences from $8.50 to $11.00 and gave the stock a “neutral” rating in a research report on Thursday, August 8th. Finally, Morgan Stanley cut Maravai LifeSciences from an “overweight” rating to an “equal weight” rating and lowered their price target for the stock from $11.00 to $10.00 in a research report on Tuesday, August 13th. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $10.67.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.